These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 21273305)

  • 1. KIT signaling regulates MITF expression through miRNAs in normal and malignant mast cell proliferation.
    Lee YN; Brandal S; Noel P; Wentzel E; Mendell JT; McDevitt MA; Kapur R; Carter M; Metcalfe DD; Takemoto CM
    Blood; 2011 Mar; 117(13):3629-40. PubMed ID: 21273305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Juxtamembrane-type c-kit gene mutation found in aggressive systemic mastocytosis induces imatinib-resistant constitutive KIT activation.
    Nakagomi N; Hirota S
    Lab Invest; 2007 Apr; 87(4):365-71. PubMed ID: 17259998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The adaptor 3BP2 is required for KIT receptor expression and human mast cell survival.
    Ainsua-Enrich E; Serrano-Candelas E; Álvarez-Errico D; Picado C; Sayós J; Rivera J; Martín M
    J Immunol; 2015 May; 194(9):4309-18. PubMed ID: 25810396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit.
    Akin C; Brockow K; D'Ambrosio C; Kirshenbaum AS; Ma Y; Longley BJ; Metcalfe DD
    Exp Hematol; 2003 Aug; 31(8):686-92. PubMed ID: 12901973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit.
    Verstovsek S; Akin C; Manshouri T; Quintás-Cardama A; Huynh L; Manley P; Tefferi A; Cortes J; Giles FJ; Kantarjian H
    Leuk Res; 2006 Nov; 30(11):1365-70. PubMed ID: 16797704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib.
    Akin C; Fumo G; Yavuz AS; Lipsky PE; Neckers L; Metcalfe DD
    Blood; 2004 Apr; 103(8):3222-5. PubMed ID: 15070706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of MCL1 as a novel target in neoplastic mast cells in systemic mastocytosis: inhibition of mast cell survival by MCL1 antisense oligonucleotides and synergism with PKC412.
    Aichberger KJ; Mayerhofer M; Gleixner KV; Krauth MT; Gruze A; Pickl WF; Wacheck V; Selzer E; Müllauer L; Agis H; Sillaber C; Valent P
    Blood; 2007 Apr; 109(7):3031-41. PubMed ID: 17110460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel NF-kappaB inhibitor, IMD-0354, suppresses neoplastic proliferation of human mast cells with constitutively activated c-kit receptors.
    Tanaka A; Konno M; Muto S; Kambe N; Morii E; Nakahata T; Itai A; Matsuda H
    Blood; 2005 Mar; 105(6):2324-31. PubMed ID: 15561889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ponatinib induces apoptosis in imatinib-resistant human mast cells by dephosphorylating mutant D816V KIT and silencing β-catenin signaling.
    Jin B; Ding K; Pan J
    Mol Cancer Ther; 2014 May; 13(5):1217-30. PubMed ID: 24552773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of function of TET2 cooperates with constitutively active KIT in murine and human models of mastocytosis.
    De Vita S; Schneider RK; Garcia M; Wood J; Gavillet M; Ebert BL; Gerbaulet A; Roers A; Levine RL; Mullally A; Williams DA
    PLoS One; 2014; 9(5):e96209. PubMed ID: 24788138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial.
    Droogendijk HJ; Kluin-Nelemans HJ; van Doormaal JJ; Oranje AP; van de Loosdrecht AA; van Daele PL
    Cancer; 2006 Jul; 107(2):345-51. PubMed ID: 16779792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of oncostatin M as a STAT5-dependent mediator of bone marrow remodeling in KIT D816V-positive systemic mastocytosis.
    Hoermann G; Cerny-Reiterer S; Perné A; Klauser M; Hoetzenecker K; Klein K; Müllauer L; Gröger M; Nijman SM; Klepetko W; Valent P; Mayerhofer M
    Am J Pathol; 2011 May; 178(5):2344-56. PubMed ID: 21457934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new humanized in vivo model of KIT D816V+ advanced systemic mastocytosis monitored using a secreted luciferase.
    Bibi S; Zhang Y; Hugonin C; Mangean MD; He L; Wedeh G; Launay JM; Van Rijn S; Würdinger T; Louache F; Arock M
    Oncotarget; 2016 Dec; 7(50):82985-83000. PubMed ID: 27783996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel KIT-deficient mouse mast cell model for the examination of human KIT-mediated activation responses.
    Smrž D; Bandara G; Zhang S; Mock BA; Beaven MA; Metcalfe DD; Gilfillan AM
    J Immunol Methods; 2013 Apr; 390(1-2):52-62. PubMed ID: 23357051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib.
    Gleixner KV; Mayerhofer M; Cerny-Reiterer S; Hörmann G; Rix U; Bennett KL; Hadzijusufovic E; Meyer RA; Pickl WF; Gotlib J; Horny HP; Reiter A; Mitterbauer-Hohendanner G; Superti-Furga G; Valent P
    Blood; 2011 Aug; 118(7):1885-98. PubMed ID: 21680801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Familial systemic mastocytosis with germline KIT K509I mutation is sensitive to treatment with imatinib, dasatinib and PKC412.
    de Melo Campos P; Machado-Neto JA; Scopim-Ribeiro R; Visconte V; Tabarroki A; Duarte AS; Barra FF; Vassalo J; Rogers HJ; Lorand-Metze I; Tiu RV; Costa FF; Olalla Saad ST; Traina F
    Leuk Res; 2014 Oct; 38(10):1245-51. PubMed ID: 25139846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Involvement of transcription factor encoded by the mi locus in the expression of c-kit receptor tyrosine kinase in cultured mast cells of mice.
    Tsujimura T; Morii E; Nozaki M; Hashimoto K; Moriyama Y; Takebayashi K; Kondo T; Kanakura Y; Kitamura Y
    Blood; 1996 Aug; 88(4):1225-33. PubMed ID: 8695840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412.
    Growney JD; Clark JJ; Adelsperger J; Stone R; Fabbro D; Griffin JD; Gilliland DG
    Blood; 2005 Jul; 106(2):721-4. PubMed ID: 15790786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of proapoptotic Bim as a tumor suppressor in neoplastic mast cells: role of KIT D816V and effects of various targeted drugs.
    Aichberger KJ; Gleixner KV; Mirkina I; Cerny-Reiterer S; Peter B; Ferenc V; Kneidinger M; Baumgartner C; Mayerhofer M; Gruze A; Pickl WF; Sillaber C; Valent P
    Blood; 2009 Dec; 114(26):5342-51. PubMed ID: 19850739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT.
    Gleixner KV; Mayerhofer M; Sonneck K; Gruze A; Samorapoompichit P; Baumgartner C; Lee FY; Aichberger KJ; Manley PW; Fabbro D; Pickl WF; Sillaber C; Valent P
    Haematologica; 2007 Nov; 92(11):1451-9. PubMed ID: 18024392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.